Case closed: Neutrons settle 40-year debate on enzyme for drug design
Filter News
Area of Research
News Type
News Topics
- (-) Emergency (1)
- (-) National Security (21)
- 3-D Printing/Advanced Manufacturing (35)
- Advanced Reactors (10)
- Artificial Intelligence (38)
- Big Data (17)
- Bioenergy (31)
- Biology (29)
- Biomedical (12)
- Biotechnology (7)
- Buildings (14)
- Chemical Sciences (24)
- Clean Water (10)
- Climate Change (31)
- Composites (8)
- Computer Science (58)
- Coronavirus (4)
- Critical Materials (6)
- Cybersecurity (14)
- Decarbonization (30)
- Education (3)
- Energy Storage (29)
- Environment (62)
- Exascale Computing (17)
- Fossil Energy (2)
- Frontier (21)
- Fusion (14)
- Grid (21)
- High-Performance Computing (33)
- Hydropower (3)
- Irradiation (2)
- Isotopes (12)
- Machine Learning (20)
- Materials (59)
- Materials Science (36)
- Mathematics (2)
- Mercury (3)
- Microelectronics (2)
- Microscopy (12)
- Molten Salt (2)
- Nanotechnology (13)
- Net Zero (5)
- Neutron Science (50)
- Nuclear Energy (38)
- Partnerships (24)
- Physics (20)
- Polymers (6)
- Quantum Computing (12)
- Quantum Science (19)
- Renewable Energy (2)
- Security (5)
- Simulation (29)
- Software (1)
- Space Exploration (8)
- Summit (18)
- Sustainable Energy (25)
- Transportation (30)
Media Contacts
U2opia Technology, a consortium of technology and administrative executives with extensive experience in both industry and defense, has exclusively licensed two technologies from ORNL that offer a new method for advanced cybersecurity monitoring in real time.
The word “exotic” may not spark thoughts of uranium, but Tyler Spano’s investigations of exotic phases of uranium are bringing new knowledge to the nuclear nonproliferation industry.